ID AACC3_PSEAI Reviewed; 271 AA. AC P29808; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 01-APR-1993, sequence version 1. DT 28-JUN-2023, entry version 65. DE RecName: Full=Aminoglycoside N(3)-acetyltransferase III {ECO:0000303|PubMed:1649572}; DE EC=2.3.1.81 {ECO:0000269|PubMed:1649572, ECO:0000269|PubMed:35921328}; DE AltName: Full=AAC(3)-IIIa {ECO:0000303|PubMed:35921328}; DE AltName: Full=ACC(3)-III {ECO:0000303|PubMed:1649572}; DE AltName: Full=Aminocyclitol 3-N-acetyltransferase type III; DE AltName: Full=Aminoglycoside acetyltransferase (3)-IIIa {ECO:0000303|PubMed:35921328}; DE AltName: Full=Gentamicin-(3)-N-acetyl-transferase; GN Name=aacC3 {ECO:0000303|PubMed:1649572}; OS Pseudomonas aeruginosa. OC Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales; OC Pseudomonadaceae; Pseudomonas. OX NCBI_TaxID=287; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND RP SUBSTRATE SPECIFICITY. RC STRAIN=PST-I {ECO:0000303|PubMed:1649572}; RX PubMed=1649572; DOI=10.1128/aac.35.5.892; RA Vliegenthart J.S., Ketelaar-Van Gaalen P.A.G., van de Klundert J.A.M.; RT "Nucleotide sequence of the aacC3 gene, a gentamicin resistance determinant RT encoding aminoglycoside-(3)-N-acetyltransferase III expressed in RT Pseudomonas aeruginosa but not in Escherichia coli."; RL Antimicrob. Agents Chemother. 35:892-897(1991). RN [2] {ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, ECO:0007744|PDB:7MQM} RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH COENZYME A; RP GENTAMICIN; RIBOSTAMYCIN AND SISOMICIN, FUNCTION, CATALYTIC ACTIVITY, RP SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND RP MUTAGENESIS OF TYR-64; ASP-72; GLU-123; TYR-146 AND ASP-170. RX PubMed=35921328; DOI=10.1371/journal.pone.0269684; RA Zielinski M., Blanchet J., Hailemariam S., Berghuis A.M.; RT "Structural elucidation of substrate-bound aminoglycoside acetyltransferase RT (3)-IIIa."; RL PLoS ONE 17:e0269684-e0269684(2022). CC -!- FUNCTION: Resistance to antibiotics containing the 2-deoxy-streptamine CC ring including dibekacin, gentamicin, kanamycin, sisomicin, tobramycin CC and neomycin, but not to amikacin or netilmicin (PubMed:1649572). CC Acetylates a broad range of both 4,5- and 4,6-disubstituted CC aminoglycosides, including neomycin, paromomycin, ribostamycin, CC sisomicin, gentamicin, tobramycin and kanamycin, with no preference of CC one disubstitution over the other. Acetylates sisomicin and kanamycin CC most and least efficiently, respectively. Does not modify plazomicin CC (PubMed:35921328). {ECO:0000269|PubMed:1649572, CC ECO:0000269|PubMed:35921328}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2-deoxystreptamine antibiotic + acetyl-CoA = an N(3')- CC acetyl-2-deoxystreptamine antibiotic + CoA + H(+); CC Xref=Rhea:RHEA:12665, ChEBI:CHEBI:15378, ChEBI:CHEBI:57287, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:57921, ChEBI:CHEBI:77452; EC=2.3.1.81; CC Evidence={ECO:0000269|PubMed:1649572, ECO:0000269|PubMed:35921328}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12666; CC Evidence={ECO:0000269|PubMed:1649572, ECO:0000269|PubMed:35921328}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=6.6 uM for neomycin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=6.7 uM for paromomycin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=7.9 uM for ribostamycin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=10.9 uM for sisomicin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=10.1 uM for gentamicin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=7 uM for kanamycin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC KM=6.6 uM for tobramycin (at pH 6.5 and 22 degrees Celsius) CC {ECO:0000269|PubMed:35921328}; CC Note=kcat is 6.15 sec(-1) with neomycin as substrate. kcat is 5.52 CC sec(-1) with paromomycin as substrate. kcat is 5.38 sec(-1) with CC ribostamycin as substrate. kcat is 10.48 sec(-1) with sisomicin as CC substrate. kcat is 8.18 sec(-1) with gentamicin as substrate. kcat is CC 4.45 sec(-1) with kanamycin as substrate. kcat is 5.68 sec(-1) with CC tobramycin as substrate. {ECO:0000269|PubMed:35921328}; CC -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:35921328}. CC -!- SIMILARITY: Belongs to the antibiotic N-acetyltransferase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X55652; CAA39184.1; -; Genomic_DNA. DR PIR; S18730; S18730. DR RefSeq; WP_063840261.1; NG_047241.1. DR PDB; 7MQK; X-ray; 1.60 A; A/B/C/D=1-271. DR PDB; 7MQL; X-ray; 1.60 A; A/B/C/D=1-271. DR PDB; 7MQM; X-ray; 1.60 A; A/B/C/D=1-271. DR PDB; 7Q0Q; X-ray; 1.96 A; A/B=1-269. DR PDB; 7Q10; X-ray; 1.82 A; A/B=1-269. DR PDB; 7Q1D; X-ray; 1.43 A; A/B/C/D=1-271. DR PDB; 7Q1X; X-ray; 1.45 A; A/B=1-271. DR PDBsum; 7MQK; -. DR PDBsum; 7MQL; -. DR PDBsum; 7MQM; -. DR PDBsum; 7Q0Q; -. DR PDBsum; 7Q10; -. DR PDBsum; 7Q1D; -. DR PDBsum; 7Q1X; -. DR AlphaFoldDB; P29808; -. DR SMR; P29808; -. DR KEGG; ag:CAA39184; -. DR GO; GO:0046353; F:aminoglycoside 3-N-acetyltransferase activity; IDA:UniProtKB. DR GO; GO:0120225; F:coenzyme A binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:1901742; P:2-deoxystreptamine metabolic process; IDA:UniProtKB. DR GO; GO:0046356; P:acetyl-CoA catabolic process; IDA:UniProtKB. DR GO; GO:0016999; P:antibiotic metabolic process; IDA:UniProtKB. DR GO; GO:0071236; P:cellular response to antibiotic; IDA:UniProtKB. DR InterPro; IPR003679; Amioglycoside_AcTrfase. DR InterPro; IPR028345; Antibiotic_NAT-like. DR PANTHER; PTHR11104; AMINOGLYCOSIDE N3-ACETYLTRANSFERASE; 1. DR PANTHER; PTHR11104:SF0; SPBETA PROPHAGE-DERIVED AMINOGLYCOSIDE N(3')-ACETYLTRANSFERASE-LIKE PROTEIN YOKD; 1. DR Pfam; PF02522; Antibiotic_NAT; 1. DR SUPFAM; SSF110710; TTHA0583/YokD-like; 1. PE 1: Evidence at protein level; KW 3D-structure; Acyltransferase; Antibiotic resistance; Transferase. FT CHAIN 1..271 FT /note="Aminoglycoside N(3)-acetyltransferase III" FT /id="PRO_0000068546" FT BINDING 31 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 32 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 33 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 34 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 35 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 64 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 72 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQM" FT BINDING 102 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQL, ECO:0007744|PDB:7MQM" FT BINDING 104 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 105 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 109 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 123 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 146 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 170 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQL, ECO:0007744|PDB:7MQM" FT BINDING 171 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQM" FT BINDING 173 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 176 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 212 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT BINDING 213 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQL" FT BINDING 221 FT /ligand="a 2-deoxystreptamine antibiotic" FT /ligand_id="ChEBI:CHEBI:77452" FT /evidence="ECO:0000269|PubMed:35921328, FT ECO:0007744|PDB:7MQK, ECO:0007744|PDB:7MQL, FT ECO:0007744|PDB:7MQM" FT MUTAGEN 64 FT /note="Y->F: No effect in catalytic activity with FT gentamicin as substrate." FT /evidence="ECO:0000269|PubMed:35921328" FT MUTAGEN 72 FT /note="D->W: No effect in catalytic activity with FT gentamicin as substrate." FT /evidence="ECO:0000269|PubMed:35921328" FT MUTAGEN 123 FT /note="E->F: Loss of catalytic activity with gentamicin as FT substrate." FT /evidence="ECO:0000269|PubMed:35921328" FT MUTAGEN 146 FT /note="Y->F: No effect in catalytic activity with FT gentamicin as substrate." FT /evidence="ECO:0000269|PubMed:35921328" FT MUTAGEN 170 FT /note="D->F: No effect in catalytic activity with FT gentamicin as substrate." FT /evidence="ECO:0000269|PubMed:35921328" FT HELIX 10..20 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 27..32 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 34..37 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 44..55 FT /evidence="ECO:0007829|PDB:7MQK" FT TURN 56..58 FT /evidence="ECO:0007829|PDB:7MQL" FT STRAND 59..64 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 74..76 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 79..88 FT /evidence="ECO:0007829|PDB:7MQK" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 105..111 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 126..130 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 133..137 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 151..157 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 161..166 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 174..181 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 185..198 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 201..210 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 221..230 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 234..239 FT /evidence="ECO:0007829|PDB:7MQK" FT STRAND 242..248 FT /evidence="ECO:0007829|PDB:7MQK" FT HELIX 249..264 FT /evidence="ECO:0007829|PDB:7MQK" SQ SEQUENCE 271 AA; 29618 MW; A66D13D364AD1484 CRC64; MTDLNIPHTH AHLVDAFQAL GIRAGQALML HASVKAVGAV MGGPNVILQA LMDALTPDGT LMMYAGWQDI PDFIDSLPDA LKAVYLEQHP PFDPATARAV RENSVLAEFL RTWPCVHRSA NPEASMVAVG RQAALLTANH ALDYGYGVES PLAKLVAIEG YVLMLGAPLD TITLLHHAEY LAKMRHKNVV RYPCPILRDG RKVWVTVEDY DTGDPHDDYS FEQIARDYVA QGGGTRGKVG DADAYLFAAQ DLTRFAVQWL ESRFGDSASY G //